Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Pharmacokinetic and local toxicity studies of liposome-encapsulated and plain mepivacaine solutions in rats

Texto completo
Autor(es):
Mostrar menos -
Tofoli, Giovana Radomille [1, 2] ; Saia Cereda, Cintia Maria [1] ; de Araujo, Daniele Ribeiro [3, 1] ; de Paula, Eneida [1] ; Brito Junior, Rui Barbosa [4] ; Pedrazzoli Junior, Jose [2] ; Meurer, Eduardo [2] ; Proenca Barros, Fabio Alessandro ; Groppo, Francisco Carlos [5] ; Volpato, Maria Cristina [5] ; Ranali, Jose [5]
Número total de Autores: 11
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, Dept Biochem, Inst Biol, BR-13083970 Campinas, SP - Brazil
[2] Univ Sao Francisco, UNIFAG Clin Pharmacol & Gastroenterol Unit, BR-12900000 Braganca Paulista, SP - Brazil
[3] Fed Univ ABC, Human & Nat Sci Ctr, Santo Andre, SP - Brazil
[4] Sao Leopoldo Mand Dent Res Inst, Dept Mol Biol, Campinas, SP - Brazil
[5] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Physiol Sci, Piracicaba, SP - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: DRUG DELIVERY; v. 17, n. 2, p. 68-76, FEB 2010.
Citações Web of Science: 6
Resumo

The pharmacokinetics and the local toxicity of commercial and liposome-encapsulated mepivacaine formulations injected intra-orally in rats were studied. Animals were divided in groups (n=4-6) and treated with 0.1 mL of the formulations: 2% mepivacaine with 1:100,000 epinephrine (MVC(2%EPI)), 3% mepivacaine (MVC(3%)), and 2% liposome-encapsulated mepivacaine (MVC(LUV)). The results showed that the 2% liposome-encapsulated mepivacaine reduced C(max), prolonged AUC(0-infinity) and t(1/2) compared with 3% plain and 2% vasoconstritor-associated mepivacaine, after intraoral injection. In addition, it was also observed that liposomal mepivacaine might protect the tissue against local inflammation evoked by plain or vasoconstrictors-associated mepivacaine, giving supporting evidence for its safety and possible clinical use in dentistry. (AU)

Processo FAPESP: 06/00121-9 - Novas formulações de anestésicos locais de liberação controlada: do desenvolvimento ao teste clínico odontológico
Beneficiário:Eneida de Paula
Modalidade de apoio: Auxílio à Pesquisa - Temático